The following stories appear in full on today's Vidyya Medical News Service Web site.
The first of many medical transcription programs that will make use of artificial intelligence, the talent of a transcriptionist and the internet has made its debut. Get contact information, company information and more in today's issue.
For more information: Instant Medical Transciption Over The Internet And Into The Patient's Record
On Friday, the UK National Institute of Clinical Excellence (NICE) announced that treatments for Alzheimer's disease should be made available as part of the management of people with mild to moderate Alzheimer's disease within the UK.
For more information: NICE Recommends Treatment For Mild To Moderate Alzheimer's Disease To Be Made Available On The NHS
One of the products recommended by NICE is Reminyl. Reminyl is used to treat the symptoms of mild to moderately severe dementia of the Alzheimer type, a disease that alters brain function. The symptoms include progressive memory loss, increasing confusion and behavioural changes. As a result, sufferers find it becomes more and more difficult to carry out their normal daily activities. Symptoms of dementia of the Alzheimer type are believed to be related to a lack of acetylcholine, a substance responsible for sending messages between brain cells. Reminyl works by increasing the amount of acetylcholine in the brain and so improves the symptoms of the disease. Get product information in today's issue.
For more information: Reminyl Product Characterisitics - UK ONLY
Patients suffering from tuberculosis now have an alternative form of treatment involving far fewer pills — currently up to 16 a day — to cure their disease. Experts writing in the January issue of the Bulletin of the World Health Organization say the new treatment, which reduces the number of tablets to as few as three or four per day, will also combat the spread of drug-resistant forms of the deadly disease, especially in the world's worst-affected countries. Proposed by the World Health Organization (WHO) in the mid-1990s but not yet adopted by all countries, the new treatment has recently become cheaper and therefore more accessible even to people in the poorest countries.
For more information: Fewer Pills Help The Medicine Go Down For TB Patients — And Combat A Deadly Epidemic
The debate over the MMR vaccine in the UK continues. Two scientists, in papers to be published on Monday, claim that the vaccine was not properly licensed in the UK. In response a UK agency, the Medicines Control Agency (MCA) has written a response to the new paper. Read the response in today's issue.
For more information: Combined Measles, Mumps And Rubella Vaccines: Response Of The Medicines Control Agency And Department Of Health To Issues Raised In Papers Published In 'Adverse Drug Reactions And Toxicological Reviews, Volume 19 No 4, 2001'
Today's Vidyya articles are:
As always, we hope you enjoy the issue.